Department of Biomedical Sciences, SNU
KOR

Faculty

  1. Home
  2. Faculty
  3. Faculty

Faculty

Seong, seung-yong

M.D., Ph.D. / Professor
Laboratory of Immunology
TEL +82-2-740-8301
E-MAIL seongsy@snu.ac.kr
WEBSITE https://immunology.snu.ac.kr

Research

Research Field
A. Development of anti-Cancer NanoBody therapeutics and modulators for NLRP3 Inflammasome
B. We published a theory that the innate Immune System recognises the hydrophobic part (Hypo) of a substance to determine the degree of damage in the tissue, thereby providing a second signal for activation of the T lymphocytes (Nature Rev. Immunol. 2004). To tesr the model experimentally, we have studied immune responses induced by water- insoluble molecules. It was applied to the development of therapeutics for inflammatory diseases by inhibiting pathways for activation of GPCR19-P2X7R-NLRP3 inflmasome. We finished phase 2 clinical trials for atopic dermatitis and COVID-19 pneumonia in 2021. A study to control dendritic cell activation and the development of anti-cancer vaccines are underway (Nat Nanotechnol. 2011). To overcome the technological limitations of anti-cancer antibody treatments, we have developed nanobody (=15 kDa) that promote the activation of T lymphocytes, and overcome immunosuppressive environment in cancer patients.
Pure Link
https://snucm.elsevierpure.com/en/persons/seung-yong-seong
Keyword
innate immunity, damage-associated molecular pattern, inflammation, atopy, pneumoniae, ulcerative colitis, NASH, single domain antibody therapeutics, cancer immunotherapy
Intensive Major
# Immune

Education

  • 1984~1990 Bachelor, Medical doctor, Seoul National University College of Medicine
  • 1990~1995 Ph.D., Department of Microbiology and Immunology, Seoul National University College of Medicine

Career

  • 1995~1998 Doctor for public health, Biomedical Research Center, Korea Institute of Science and Technology
  • 2002~2004 Research Fellow, NIAID, NIH Bethesda, USA
  • 1998~present Department of Microbiology and Immunology, Seoul National University College of Medicine

Publication

  1. Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer.
  2. Youn JI, Park SM, Park S, Kim G, Lee HJ, Son J, Hong MH, Ghaderpour A, Baik B, Islam J, Choi JW, Lee EY, Kim HR, Seo SU, Paik S, Yoon HI, Jung I, Xin CF, Jin HT, Cho BC, Seong SY, Ha SJ, Kim HR. Sci Rep. 2020 Jun 3;10(1):9050. doi: 10.1038/s41598-020-65666-x.
  3. Taurodeoxycholate Increases the Number of Myeloid-Derived Suppressor Cells That Ameliorate Sepsis in Mice.
  4. Chang S, Kim YH, Kim YJ, Kim YW, Moon S, Lee YY, Jung JS, Kim Y, Jung HE, Kim TJ, Cheong TC, Moon HJ, Cho JA, Kim HR, Han D, Na Y, Seok SH, Cho NH, Lee HC, Nam EH, Cho H, Choi M, Minato N, Seong SY. Front Immunol. 2018 Sep 18;9:1984. doi: 10.3389/fimmu.2018.01984. eCollection 2018.
  5. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy.
  6. Cho NH, Cheong TC, Min JH, Wu JH, Lee SJ, Kim D, Yang JS, Kim S, Kim YK, Seong SY. Nat Nanotechnol. 2011 Sep 11;6(10):675-82. doi: 10.1038/nnano.2011.149.
  7. Cardiolipin activates antigen-presenting cells via TLR2-PI3K-PKN1-AKT/p38-NF-kB signaling to prime antigen-specific naïve T cells in mice.
  8. Cho JA, Kim TJ, Moon HJ, Kim YJ, Yoon HK, Seong SY. Eur J Immunol. 2018 May;48(5):777-790. doi: 10.1002/eji.201747222. Epub 2018 Jan 19.
  9. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses.
  10. Seong SY, Matzinger P. Nat Rev Immunol. 2004 Jun;4(6):469-78. doi: 10.1038/nri1372.
List
KOREAN